Drug Trial Radar · NCT05690802
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
Last checked: Nov 20, 2026Latest source record: Jan 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,060
Planned (sponsor's estimate)
Start
May 16, 2022
Primary completion
May 30, 2027
Study completion May 30, 2029
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 19, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.
Conditions
- Nausea and Vomiting
Interventions
Palonosetron hydrochloride capsulesDrug
This protocol only stipulates "Palonosetron capsule containing hydrochloric acid protocol", and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Any adverse event after treatmentTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, the Air Force Medical University
Xi'an, Shaan'xi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.